Answers are grounded in this paper and cite their sources.
Treatments for lung cancer have advanced significantly over the last 2 decades, improving survival and long-term outcomes. However, lung cancer mortality remains high, and cures for metastatic disease have remained elusive. Here, we outline recent advances in our understanding of lung cancer biology and areas of interest for future therapeutic development, with a focus on resistance mechanisms, tumor heterogeneity, plasticity, minimal residual disease, and the tumor microenvironment. A comprehensive understanding of how these areas influence tumor biology will be essential for the development of future lung cancer therapies and to improve the care of lung cancer patients.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: